Drug Trial Radar · NCT07519577
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-2)
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
May 31, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
Conditions
- Chronic Rhinosinusitis With Nasal Polyposis
Interventions
CM512Biological
Administered subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse eventsTime frame: Up to week 60
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tong-Ren hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.